S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
Log in

NASDAQ:ADTXQualigen Therapeutics Stock Price, Forecast & News

$3.93
-0.15 (-3.68 %)
(As of 08/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.82
Now: $3.93▼
$4.06
50-Day Range N/A
52-Week Range
$2.83
Now: $3.93▼
$7.08
Volume174,015 shs
Average Volume348,481 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ADiTx Therapeutics, Inc., a life sciences company, focuses on developing nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients and address autoimmune diseases and allergies. The company commercializes Apoptotic DNA Immunotherapy (ADi), a nucleic acid-based technology that utilizes an approach, which mimics the way the body naturally induces tolerance to its own tissues. It also develops ADi products for organ transplantation, skin grafting, autoimmune diseases, allergies, and other applications. The company has a license agreement with Loma Linda University. ADiTx Therapeutics, Inc. was founded in 2017 and is headquartered in Loma Linda, California.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.00 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADTX
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.aditxt.com
Phone909-488-0844

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees2
Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable
$3.93
-0.15 (-3.68 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ADTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Qualigen Therapeutics (NASDAQ:ADTX) Frequently Asked Questions

Has Qualigen Therapeutics been receiving favorable news coverage?

News coverage about ADTX stock has trended neutral this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Qualigen Therapeutics earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about Qualigen Therapeutics.

Who are some of Qualigen Therapeutics' key competitors?

Some companies that are related to Qualigen Therapeutics include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Admedus (AHZ), Almirall (LBTSF), Amarantus Bioscience (AMBS), Antibe Therapeutics (VBIZF), Aortech International (RUA), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Baudax Bio (BXRXV), BerGenBio ASA (BRRGF), Biocure Technology (CURE) and Canada House Wellness Group (CHV).
View all competitors.

Who are Qualigen Therapeutics' key executives?

Qualigen Therapeutics' management team includes the following people:
  • Mr. Amro Albanna, Co- Founder, Chairman, Pres & CEO (Age 50, Pay $252k)
  • Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D., Co-founder, Chief Innovation Officer, Sec. & Director (Age 57, Pay $204k)
  • Ms. Corinne D. Pankovcin CPA, CPA, Chief Financial Officer (Age 54)
  • Ms. Rowena Albanna, Chief Operating Officer (Age 54)

What is Qualigen Therapeutics' stock symbol?

Qualigen Therapeutics trades on the NASDAQ under the ticker symbol "ADTX."

When does Qualigen Therapeutics' quiet period expire?

Qualigen Therapeutics' quiet period expires on Monday, August 10th. Qualigen Therapeutics had issued 1,226,668 shares in its public offering on June 30th. The total size of the offering was $11,040,012 based on an initial share price of $9.00. During Qualigen Therapeutics' quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Qualigen Therapeutics?

Shares of ADTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Qualigen Therapeutics' stock price today?

One share of ADTX stock can currently be purchased for approximately $3.93.

What is Qualigen Therapeutics' official website?

The official website for Qualigen Therapeutics is www.aditxt.com.

How can I contact Qualigen Therapeutics?

The company can be reached via phone at 909-488-0844.

This page was last updated on 8/5/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.